Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-01-30

Clinical Trial Update: A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and efficacy of the ALK House Dust Mite Allergy Tablet has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ALK House Dust Mite Allergy Tablet

Snippet

Sponsor: ALK-Abelló A/S | Conditions: House Dust Mite Allergy | Phase 3 | Status: COMPLETED